TRV-2026-1189Version 1 · Published

Saved · see the current record

Why this version exists

Certified into the record

The exact text we saved

This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.

TRUVACE RECORD VERSION
record: TRV-2026-1189
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-09-26T06:53:36.256432Z
status: published
lens: p_space
sector: health
headline: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning
dek: Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation. We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post…
gain_title: (none)
problem_title: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning: Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity.
trace_subject: (none)
gain_reading: (none)
gain_evidence: (none)
problem_reading: Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning: Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity.
problem_evidence: (none)
quick_read: Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.

We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status. Serum samples from 280 participants (85 benign, 82 malignant, and 113 independent follow-up patients) were analyzed over 400-1800 cm⁻ 1 .
limitation: 
tag: Evidence-backed problem
key_points: Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. | Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation. | We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status.
rundown: Rapid, low-cost tools for ovarian tumor discrimination and post-treatment assessment remain limited because conventional serum biomarkers such as CA125 have suboptimal sensitivity and specificity. Serum contains proteins, lipids, carbohydrates, and nucleic acids that generate disease-related spectrochemical fingerprints, which portable Raman spectroscopy can capture with minimal sample preparation.

We investigated serum Raman profiling for ovarian tumor discrimination and cross-sectional characterization of post-treatment disease-free status. Serum samples from 280 participants (85 benign, 82 malignant, and 113 independent follow-up patients) were analyzed over 400-1800 cm⁻ 1 .
sources:
- peer_reviewed | Analytical and Bioanalytical Chemistry | https://doi.org/10.1007/s00216-026-06823-5 | 2026-09-23
prev: 0000000000000000000000000000000000000000000000000000000000000000
SHA-256 hash
38526b18e0956b9663cc3a6369df7ae619f968fad6bbd0870f1605f6604f05e6
Previous version’s hash
0000000000000000000000000000000000000000000000000000000000000000
Check this record hasn’t been altered
How to check it yourself, without trusting this page

Download any version from /api/record/TRV-2026-1189 and hash its canonical field yourself, for example with shasum -a 256. You should get its content_hash. Each version’s text also ends with prev:and the hash of the version before it (version 1 points to 64 zeros). If anyone had changed a single character of any version after it was saved, those hashes wouldn’t line up.